Amgen : AMGN

All Amgen Articles

717 Articles

Jon C. Ogg | Dec 31, 2015 at 8:35 AM EST

5 Top Goldman Sachs Stocks to Buy for 2016

Goldman Sachs has seen many top stocks offering great rewards for 2016. The reason may be different for each, but…

Chris Lange | Dec 28, 2015 at 8:40 AM EST

Short Interest Remains Mixed in Major Biotechs

The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in…

Trey Thoelcke | Dec 23, 2015 at 12:15 PM EST

4 High-Flying Stocks That Could Fly Even Higher in 2016

Here are four stocks that, while expensive at current levels, have fundamentals good enough to continue and even exceed their…

Trey Thoelcke | Dec 18, 2015 at 7:10 AM EST

4 Top Biotech Stocks for 2016

Biotech looks set to close out 2015 as its worst performing year since 2008. But can we expect a better…

Jon C. Ogg | Dec 15, 2015 at 4:52 PM EST

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a…

Chris Lange | Dec 10, 2015 at 8:40 AM EST

Mixed Views on Major Biotech Short Interest

The November 30 short interest data have been compared with the previous report, and short interest was mixed in these…

Chris Lange | Nov 25, 2015 at 9:06 AM EST

Short Sellers Run for Cover From Major Biotechs

24/7 Wall St. has reviewed the short interest data on the top biotech companies.

Chris Lange | Nov 11, 2015 at 7:45 AM EST

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.

Chris Lange | Oct 28, 2015 at 4:41 PM EDT

Amgen Beats Earnings With Solid Outlook For 2015

ThinkstockAmgen Inc. (NASDAQ: AMGN) released its third quarter earnings report Wednesday after the markets closed. The biotech giant had $2.72…

Chris Lange | Oct 28, 2015 at 11:25 AM EDT

What to Expect From Amgen Earnings

Amgen is scheduled to report its third-quarter financial results after the markets close on Wednesday.

Chris Lange | Oct 27, 2015 at 8:10 AM EDT

Short Sellers Become More Selective on Leading Biotechs

The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected…

Chris Lange | Oct 23, 2015 at 1:35 PM EDT

Why Amgen’s Future Is Looking Bright

Amgen is slowly getting closer to an FDA final decision for its first-of-a-kind cancer therapy, talimogene laherparepvec (T-Vec).

Lee Jackson | Oct 20, 2015 at 10:05 AM EDT

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also…

Chris Lange | Oct 12, 2015 at 8:20 AM EDT

Short Sellers Increase Bets in Major Biotechs

The September 30 short interest data have been compared with the previous figures, and short interest increased in most of…

Lee Jackson | Oct 9, 2015 at 10:05 AM EDT

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.

1 … 24 25 26 27 28 … 48

Amgen : AMGN

All Amgen Articles

5 Top Goldman Sachs Stocks to Buy for 2016

Short Interest Remains Mixed in Major Biotechs

4 High-Flying Stocks That Could Fly Even Higher in 2016

4 Top Biotech Stocks for 2016

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Mixed Views on Major Biotech Short Interest

Short Sellers Run for Cover From Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Amgen Beats Earnings With Solid Outlook For 2015

What to Expect From Amgen Earnings

Short Sellers Become More Selective on Leading Biotechs

Why Amgen’s Future Is Looking Bright

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Short Sellers Increase Bets in Major Biotechs

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Arizonans Don’t Retire in Scottsdale. Here’s Where They Actually Go

At 64, He Moved His 401(k) Away From Stocks. Wall Street May Bring AI Risk Back Through the Bond Side.

Two Latin Words on Your Beneficiary Form Decide Whether Your Grandchildren Inherit Their Late Parent’s Share or Watch It Get Split Among the Aunts and Uncles

Arizonans Don't Retire in Scottsdale. Here's Where They Actually Go

At 64, He Moved His 401(k) Away From Stocks. Wall Street May Bring AI Risk Back Through the Bond Side.

Arizonans Don’t Retire in Scottsdale. Here’s Where They Actually Go

At 64, He Moved His 401(k) Away From Stocks. Wall Street May Bring AI Risk Back Through the Bond Side.

Amgen : AMGN

All Amgen Articles

5 Top Goldman Sachs Stocks to Buy for 2016

Short Interest Remains Mixed in Major Biotechs

4 High-Flying Stocks That Could Fly Even Higher in 2016

4 Top Biotech Stocks for 2016

How Amgen’s Larger-Than-Expected Dividend Hike Stacks Up to Peers

Mixed Views on Major Biotech Short Interest

Short Sellers Run for Cover From Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Amgen Beats Earnings With Solid Outlook For 2015

What to Expect From Amgen Earnings

Short Sellers Become More Selective on Leading Biotechs

Why Amgen’s Future Is Looking Bright

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Short Sellers Increase Bets in Major Biotechs

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Arizonans Don’t Retire in Scottsdale. Here’s Where They Actually Go

At 64, He Moved His 401(k) Away From Stocks. Wall Street May Bring AI Risk Back Through the Bond Side.

Two Latin Words on Your Beneficiary Form Decide Whether Your Grandchildren Inherit Their Late Parent’s Share or Watch It Get Split Among the Aunts and Uncles

Featured Reads

Arizonans Don't Retire in Scottsdale. Here's Where They Actually Go

At 64, He Moved His 401(k) Away From Stocks. Wall Street May Bring AI Risk Back Through the Bond Side.